Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(12 sites)

Australia

Royal North Shore Hospital, Sydney, New South Wales

Wollongong Hospital, Wollongong, New South Wales

Royal Brisbane and Womens Hospital, Brisbane, Queensland

The Queen Elizabeth Hospital, Adelaide, South Australia

Peter MacCallum Cancer Centre, Melbourne, Victoria

Fiona Stanley Hospital, Perth, Western Australia

Canada

BC Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia

London Health Sciences Centre Research Institute (LHSCRI), London, Ontario

Ottawa Hospital Research Institute, Ottawa, Ontario

Odette Cancer Centre Sunnybrook Health Sciences Centre, Toronto, Ontario

Allan Blair Cancer Centre, Regina, Saskatchewan

Saskatoon Cancer Centre, Saskatoon, Saskatchewan